Many Older Patients Can Ditch Common Thyroid Drug, Study Suggests

Published Date: 11 May 2026

Experts call for better guidance on levothyroxine initiation, deprescribing

Read Full News

Latest News

Novo Nordisk Says Wegovy Approved in China for MASH

Denmark's Novo Nordisk ⁠said on Thursday its blockbuster ⁠weight-loss drug Wegovy had ⁠been approved ‌in China as the first GLP-1 RA class of drugs for the ‌treatment of MASH.

Obesity Rises Faster in Young Adults, Steeper in Older Adults

Obesity is increasing faster among young adults worldwide, even as older adults still carry the greater overall burden, a new analysis of 196 countries over three decades finds.

Diabetes Care in Danish Care Homes May Miss the Mark

About 1 in 8 Danish care home residents with T2D admitted from 2018 to 2023 used glucose-lowering drugs, and most continued treatment despite having A1c levels below recommended targets.

High Semaglutide Dropout Rates Signal Adherence Challenge

With nearly half of patients discontinuing semaglutide within 12 months — especially younger adults — clinicians face a growing challenge in sustaining long-term treatment.

Menopausal Symptoms Worse in Women With Type 2 Diabetes

An observational study finds a higher number of symptoms and greater severity among midlife women with type 2 diabetes than among those without.

Weekly Basal Insulin + Semaglutide Combo May Benefit T2D

Novo Nordisk’s phase 3b trial shows once-weekly IcoSema improves glycemic control and weight with less hypoglycemia than insulin glargine U100 in adults with type 2 diabetes.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Latest News

Denmark's Novo Nordisk ⁠said on Thursday its blockbuster ⁠weight-loss drug Wegovy had ⁠been approved ‌in China as the first GLP-1 RA class of drugs for the ‌treatment of MASH.

Obesity is increasing faster among young adults worldwide, even as older adults still carry the greater overall burden, a new analysis of 196 countries over three decades finds.

About 1 in 8 Danish care home residents with T2D admitted from 2018 to 2023 used glucose-lowering drugs, and most continued treatment despite having A1c levels below recommended targets.

With nearly half of patients discontinuing semaglutide within 12 months — especially younger adults — clinicians face a growing challenge in sustaining long-term treatment.

An observational study finds a higher number of symptoms and greater severity among midlife women with type 2 diabetes than among those without.

Novo Nordisk’s phase 3b trial shows once-weekly IcoSema improves glycemic control and weight with less hypoglycemia than insulin glargine U100 in adults with type 2 diabetes.

News All Time

How to Help Manage Depression After GLP-1 Weight Regain

Offer realistic expectations when medication use ends and provide the tools to remain on track.
HTTP error: 503

EMA Probes Injectable Iron Medicines for Bone Risks

European regulators launched a safety review of injectable iron medicines following reports of severe hypophosphatemia and osteomalacia.

US FDA Is Working With Manufacturers to Boost Estrogen Patch Supply Amid Access Concerns

The U.S. health regulator said on Thursday it is working with all six manufacturers to increase the supply of estradiol transdermal patches, ⁠used to treat menopause...

Medicare A1c Coverage Boosts Prediabetes Detection

Since Medicare began covering A1c for diabetes screening in 2024, use of the test and detection of prediabetes have risen dramatically among older adults.

GLP-1 Meds Linked to Symptomatic Remission in UC

GLP-1 receptor agonist therapy is linked to higher symptomatic remission rates among patients with ulcerative colitis, with benefits appearing independent of weight loss.
HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503

Early Childhood Obesity Linked to Adolescent Obesity Risk

Obesity during early childhood is strongly linked to obesity by adolescence, whereas overweight carries a far smaller risk for progression — even after a recent BMI rise from normal weight.

600,000 Seniors Have Signed Up for Obesity Drugs Under New Medicare Program

U.S. Centers for ⁠Medicare and Medicaid Services Administrator ⁠Dr. Mehmet Oz said ⁠on Monday ‌that 600,000 seniors have signed up to receive GLP-1 weight ‌loss medications...

Hims & Hers Offers GLP-1s, Men's Health Treatments in Australia

Telehealth company Hims & Hers has begun offering GLP-1 weight-loss drugs and other treatments ⁠to men in Australia as it continues to expand its international business.

Time-Restricted Eating Helps Sustain Weight Loss

New research shows an 8-hour eating window can help sustain weight loss for a year. Meal timing, alongside diet quality and exercise may be a useful, personalized tool.

Recommended News For You

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

Combination therapy improves outcomes for advanced triple-negative breast cancer

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?

An Intimate Life of Medical Innovation and Charity.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

Recommended Articles For You

Rehabilitation of Hand Dexterity Following Hematologic Treatment-Associated Deconditioning 

Bone-on-a-Chip Systems: A Revolutionary Approach to Modeling Hematological Cancers 

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice 

From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women

1.

Tumor Ecosystem Rewiring Through Adaptive Therapeutics

2.

Seeing the Unseen: Examining Chancroid Through Images

3.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

4.

The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology

5.

Decoding Granular Cell Tumor: What You Need to Know

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Advances in Modern Cancer Treatment

2.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

3.

Thromboprophylaxis In Medical Settings

4.

Navigating the Complexities of Ph Negative ALL - Part VII

5.

Managing Common Side Effects During Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot